We are live on ! Find out more
TMDX icon

Transmedics

428 hedge funds and large institutions have $4.53B invested in Transmedics in 2025 Q4 according to their latest regulatory filings, with 89 funds opening new positions, 156 increasing their positions, 127 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 45

68% more call options, than puts

Call options by funds: $98.1M | Put options by funds: $58.2M

23% more repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 127

10% more funds holding

Funds holding: 388428 (+40)

9% more capital invested

Capital invested by funds: $4.17B → $4.53B (+$359M)

0.1% less ownership

Funds ownership: 108.93%108.83% (-0.1%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
428
Holders Change
+40
Holders Change %
+10.31%
% of All Funds
5.2%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.02%
New
89
Increased
156
Reduced
127
Closed
45
Calls
$98.1M
Puts
$58.2M
Net Calls
+$39.8M
Net Calls Change
+$25.2M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$656M +$7.99M +63,634 +1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$618M +$1.59M +12,666 +0.3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$439M -$41.2K -328 -0%
State Street
4
State Street
Massachusetts
$155M -$553K -4,408 -0.3%
UBS AM
5
UBS AM
Illinois
$121M -$9.11M -72,614 -7%
Goldman Sachs
6
Goldman Sachs
New York
$118M +$32.9M +262,353 +37%
NAMI
7
Nomura Asset Management International
Pennsylvania
$101M +$104M +832,241 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$99.3M +$364K +2,903 +0.4%
DCM
9
Driehaus Capital Management
Illinois
$86.6M -$3.28M -26,117 -4%
HRCM
10
Hood River Capital Management
Florida
$84M +$1.5M +11,920 +2%
Invesco
11
Invesco
Georgia
$83.3M +$37.5M +298,770 +77%
Morgan Stanley
12
Morgan Stanley
New York
$81.2M +$15.1M +119,942 +22%
UBS Group
13
UBS Group
Switzerland
$80.2M -$24.7M -196,767 -23%
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$69.3M +$21.6M +171,810 +43%
EAM
15
Eventide Asset Management
Massachusetts
$66.7M +$122K +971 +0.2%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$59.6M +$4.86M +38,717 +9%
Two Sigma Investments
17
Two Sigma Investments
New York
$53M -$25M -199,425 -31%
Wellington Management Group
18
Wellington Management Group
Massachusetts
$52.7M +$27.3M +217,180 +100%
JP Morgan Chase
19
JP Morgan Chase
New York
$45.7M -$2.15M -17,095 -4%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$44.1M -$7.65M -61,000 -14%
EA
21
Emerald Advisers
Pennsylvania
$42.7M -$4.55M -36,239 -9%
Northern Trust
22
Northern Trust
Illinois
$41.3M -$1.04M -8,253 -2%
WA
23
Wasatch Advisors
Utah
$40.4M +$834K +6,646 +2%
Charles Schwab
24
Charles Schwab
California
$39.3M +$281K +2,239 +0.7%
Baillie Gifford & Co
25
Baillie Gifford & Co
United Kingdom
$38.5M +$7M +55,754 +21%

TMDX Hedge Fund Activity: Q4 2025 in Review

428 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Transmedics (TMDX) for Q4 2025, worth a combined $4.53B — up 8.6% from $4.17B a quarter earlier.

Buyers outnumbered sellers: 89 funds opened new TMDX positions and 45 closed out — a net gain of 44 holders — while 156 added to existing stakes and 127 trimmed.

The largest buyer was Invesco, adding an estimated $37.5M. The largest seller was Macquarie Group, exiting entirely with an estimated $102M sold.

  • 428 institutional investors held Transmedics (TMDX) as of Q4 2025, up from 388 in Q3 2025.
  • Funds reported $4.53B of Transmedics stock for Q4 2025, up 8.6% quarter-over-quarter.
  • 89 funds opened new Transmedics positions in Q4 2025 and 45 closed out, a net change of +44 holders.
  • The largest Transmedics buyer in Q4 2025 was Invesco, an estimated $37.5M added.
  • The largest Transmedics seller in Q4 2025 was Macquarie Group, an estimated $102M sold.

Based on aggregated 13F filings for Q4 2025.